April 2012 Drug Information Update - Pharmacy Benefits ...
April 2012 Drug Information Update - Pharmacy Benefits ...
April 2012 Drug Information Update - Pharmacy Benefits ...
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
500 mg, 100 count (NDC 63304-0726-01)<br />
Biaxin immediate-release tablets, Abbott<br />
250 mg, 100 count unit dose (NDC 00074-3368-11) - discontinued<br />
Reason for the Shortage<br />
• Ranbaxy has an import ban on their products.<br />
• Apotex import ban has been lifted, but the company has not resumed production of<br />
clarithromycin immediate-release tablets.<br />
• Abbott, Mylan, and Sandoz could not provide a reason for the shortage.<br />
Article link: http://www.ashp.org/<strong>Drug</strong>Shortages/Current/Bulletin.aspx?id=726<br />
Source: www.ashp.org<br />
Paclitaxel Injection<br />
March 15, <strong>2012</strong><br />
Products Affected - Description<br />
Paclitaxel 6 mg/mL injection, APP<br />
30 mg/5 mL vial (NDC 63323-0763-05)<br />
150 mg/16.7 mL vial (NDC 63323-0763-05)<br />
300 mg/50 mL vial (NDC 63323-0763-50)<br />
Paclitaxel 6 mg/mL injection, Bedford<br />
30 mg/5 mL vial (NDC 55390-0114-05)<br />
100 mg/16.7 mL vial (NDC 55390-0114-20)<br />
300 mg/50 mL vial (NDC 55390-0114-50)<br />
30 mg/5 mL Novaplus vial (NDC 55390-0304-05)<br />
100 mg/16.7 mL Novaplus vial (NDC 55390-0304-20)<br />
300 mg/50 mL Novaplus vial (NDC 55390-0304-50)<br />
Paclitaxel 6 mg/mL injection, Hospira<br />
100 mg/16.7 mL vial (NDC 61703-0342-22)<br />
Paclitaxel 6 mg/mL injection, Sagent<br />
30 mg/5 mL vial (NDC 25021-0213-05)<br />
100 mg/16.7 mL vial (NDC 25021-0213-07)<br />
Paclitaxel 6 mg/mL injection, Sandoz<br />
30 mg/5 mL vial (NDC 66578-0043-01)<br />
100 mg/16.7 mL vial (NDC 66578-0043-02)<br />
300 mg/50 mL vial (NDC 66578-0043-03)<br />
Paclitaxel 6 mg/mL injection, Teva<br />
30 mg/5 mL vial (NDC 00703-4764-01)<br />
Reason for the Shortage<br />
• APP has paclitaxel on shortage due to increase demand for the product.<br />
• Ben Venue voluntarily suspended all manufacturing and distribution in mid-November, 2011 on a<br />
temporary basis for maintenance and requalification of equipment. Product will become available<br />
in stages as production resumes.<br />
• Bedford Laboratories has multiple products affected by this temporary suspension of<br />
manufacturing. Bedford will have the affected, as well as the available products, listed on their<br />
website and are updating this information as it changes.<br />
• Teva has paclitaxel on shortage due to manufacturing delays.<br />
• Sandoz has paclitaxel on back order due to a raw material shortage.<br />
• Hospira has paclitaxel on back order due to increased demand for the product.<br />
• Sagent cannot provide a reason for the shortage of paclitaxel.<br />
45
Change language